# Flu A, Flu B + SARS-CoV-2 at Your Fingertips 

## One Test, Three Results, 15 Minutes

Accurate, objective and automated results in 15 minutes

Excellent performance compared to viral culture or molecular methods

Flexible, dual mode testing for high
throughput in variety of laboratory environments

Track via secure, remote instrument management with Virena ${ }^{\circledR}$

Integrated data management
automatically stores test and user history


User and patient ID captured with onboard barcode scanner


## Nasal Swab Procedure



## Sofia 2 Development Modes

WALK AWAY Mode - Walk away and multitask


## Sofia 2 Flu + SARS Antigen FIA*

- Nasal specimens
- Accurate detection with direct samples
- Results in 15 minutes
- Kit includes 25 sterile nasal swabs and a set of positive and negative control swabs
- Room temperature storage

READ NOW Mode - Batch multiple samples per hour


Sofia 2 Flu + SARS Antigen FIA Clinical Performance*

|  | Sample Type | Sens/PPA* | Spec/NPA* |
| :--- | :---: | :---: | :---: |
| Influenza A | Nasal | $90 \%$ | $95 \%$ |
| Influenza B | Nasal | $89 \%$ | $96 \%$ |
| SARS-CoV-2* | Nasal | $95.2 \%^{*}$ | $100 \%^{*}$ |

*Results for SARS-CoV-2 are expressed as PPA/NPA and were tested on nasal swabs in the study, however, may also be used with NP swabs.

Refer to the Package Insert for additional performance claims.


[^0]
[^0]:    The Sofia 2 Flu + SARS Antigen FIA has not been FDA cleared or approved but has been authorized by the FDA under an EUA for use by authorized laboratories for the detection of proteins from SARS-CoV-2, and influenza, not for any other viruses or pathogens. This assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

